Abstract 992P
Background
IMbrave150 trial confirmed the better clinical benefits with 1200 mg of atezolizumab plus 15 mg/kg of bevacizumab (Atezo/Bev) than with sorafenib for patients with unresectable hepatocellular carcinoma (HCC). However, effectiveness and safety with low-dose bevacizumab still remained uncertain in real-world practice. Our study aimed to investigate this issue.
Methods
We conducted a retrospective cohort study by using the Chang Gung Research Database, a multi-institutional electronic medical records database in Taiwan. The eligible patients were locally advanced metastatic and/or unresectable HCC with newly prescribed Atezo/Bev as first-line treatment between January 1, 2020 and December 31, 2022. The index date was the time Atezo/Bev initiation. We classified patients into: (1) the standard-dose group (15 mg/kg bevacizumab), and (2) the low-dose group (< 15 mg/kg bevacizumab). The primary outcome was overall survival (OS) and secondary outcomes included progression-free survival (PFS) and bleeding events. We applied Kaplan-Meier curve to estimate median OS and PFS. Moreover, we used Cox regression model to analyze hazard ratio (HR) and 95% confidence interval (CI) between two group.
Results
We enrolled total 151 patients in our analysis, with 15 patients newly receiving standard-dose bevacizumab (mean [SD] age: 58.5 [10.8]; male: 60.0%) and 136 patients receiving low-dose bevacizumab (mean [SD] age: 61.9 [11.6]; male: 77.9%). With a median 10.1 months of follow-up, the median OS was 14.9 months (95% CI: 1.4 to not reached [NR]) for standard-dose group and 11.2 months (95% CI: 8.8 to 14.3) for low-dose group (HR: 0.78, 95% CI: 0.38-1.56, P=0.48). Also, the median PFS (8.4 vs. 5.7 months, P=0.59) and the rate for bleeding events (20.0% vs. 25.0%, P=0.23) were similar in both groups.
Conclusions
Our study demonstrated no significant difference in OS, PFS and bleeding events between patients receiving standard-dose and low-dose bevacizumab in combination with atezolizumab in real-world clinical practice. Further large scale study was suggested to confirm our findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
832P - Characterisation of EXS73565: A potent and selective MALT1 inhibitor with low drug-drug interaction risk and potential in lymphoma
Presenter: Major Gooyit
Session: Poster session 18
833P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster session 18
834P - Phase II clinical study of VR-CAP regimen for first-line treatment of marginal zone lymphoma
Presenter: Junfeng Chu
Session: Poster session 18
835P - A safe and effective immunochemotherapy with oral sobuzoxane and etoposide for untreated diffuse large B cell lymphoma patients aged 80 and over
Presenter: Kaname Miyashita
Session: Poster session 18
838P - Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Presenter: Olalekan Oluwole
Session: Poster session 18
840P - Genomic landscape, immune characteristics and prognostic mutation signature of extranodal NK/T cell lymphoma, nasal type in China
Presenter: Yue Chai
Session: Poster session 18
841P - Ki67-revised risk index to risk-stratify patients with extra-nodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 18